ATE432359T1 - Modulation der s6-kinaseaktivität zur behandlung von adipositas - Google Patents

Modulation der s6-kinaseaktivität zur behandlung von adipositas

Info

Publication number
ATE432359T1
ATE432359T1 AT03773650T AT03773650T ATE432359T1 AT E432359 T1 ATE432359 T1 AT E432359T1 AT 03773650 T AT03773650 T AT 03773650T AT 03773650 T AT03773650 T AT 03773650T AT E432359 T1 ATE432359 T1 AT E432359T1
Authority
AT
Austria
Prior art keywords
obesity
modulation
treatment
kinase activity
kinase
Prior art date
Application number
AT03773650T
Other languages
English (en)
Inventor
Francesca Frigerio
Stefano Fumagalli
Sara Kozma
Melanie Sticker-Jantscheff
George Thomas
Sung Um
Original Assignee
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0224338.4A external-priority patent/GB0224338D0/en
Application filed by Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung
Application granted granted Critical
Publication of ATE432359T1 publication Critical patent/ATE432359T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03773650T 2002-10-18 2003-10-17 Modulation der s6-kinaseaktivität zur behandlung von adipositas ATE432359T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0224338.4A GB0224338D0 (en) 2002-10-18 2002-10-18 Modulation of S6 kinase activity for the treatment of obesity
US49722703P 2003-08-22 2003-08-22
PCT/EP2003/011554 WO2004035815A1 (en) 2002-10-18 2003-10-17 Modulation of s6 kinase activity for the treatment of obestiy

Publications (1)

Publication Number Publication Date
ATE432359T1 true ATE432359T1 (de) 2009-06-15

Family

ID=32109253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03773650T ATE432359T1 (de) 2002-10-18 2003-10-17 Modulation der s6-kinaseaktivität zur behandlung von adipositas

Country Status (7)

Country Link
EP (1) EP1556505B1 (de)
JP (1) JP2006502744A (de)
AT (1) ATE432359T1 (de)
AU (1) AU2003282035A1 (de)
DE (1) DE60327793D1 (de)
ES (1) ES2328033T3 (de)
WO (1) WO2004035815A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
EP1908465B1 (de) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen
WO2013017656A1 (en) * 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017980A4 (de) * 1996-03-12 2002-09-18 Smithkline Beecham Corp Verfahren zur identifizierung pharmazeutisch aktiver verbindungen
EP1100929B1 (de) * 1998-08-04 2011-02-09 Ludwig Institute For Cancer Research Identifizierung und funktionelle charakterisierung einer ribosomalen s6 proteinkinase
AU4683700A (en) * 1999-04-30 2000-11-17 Beth Israel Deaconess Medical Center Decreasing adipose mass by altering rsk2 activity
JP2003516760A (ja) * 1999-12-02 2003-05-20 ユニヴァーシティー オブ ダンディー プロテインキナーゼ調節

Also Published As

Publication number Publication date
EP1556505B1 (de) 2009-05-27
EP1556505A1 (de) 2005-07-27
ES2328033T3 (es) 2009-11-06
JP2006502744A (ja) 2006-01-26
AU2003282035A1 (en) 2004-05-04
DE60327793D1 (de) 2009-07-09
WO2004035815A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE278399T1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE287731T1 (de) Inhibition von histondeacetylase zur behandlung von herzhypertrophie
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE502004004659D1 (de) Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
IL183514A0 (en) Pyrrolidine inhibitors of iap
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE370738T1 (de) Verwendung von eplerenon zur behandlung von restenose
DE60213116D1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556505

Country of ref document: EP

REN Ceased due to non-payment of the annual fee